The results indicated that lower expression levels of METTL3 and METTL14 were associated with increased lymph node metastasis (N1‐N2), enhanced distal metastasis (M1), and poorer patient survival (Figure 1E–J). Here, METTL3 is linked to metastatic malignant neoplasm in the lymph nodes.